Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Bioventus Inc.BVS · Entity 4996 | Fmr. SVP & Chief Science Off. | March 14, 2022 | April 21, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Bioventus Inc.
Report date March 14, 2022 · Filed April 21, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 35,545 |
Reported balance
After 2022-03-14 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-03-14 · Grant · Acquired 35,545 · Balance 35,545 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock. F2: The RSUs and options, as applicable, shall vest in four approximately equal installments on each of the first four anniversaries of March 14, 2022, in each case subject to the Reporting Person continuing in service through the applicable vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.16 · Expires 2032-03-13 | Direct | 96,133 |
Reported balance
After 2022-03-14 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-03-14 · Grant · Acquired 96,133 · Balance 96,133 F2: The RSUs and options, as applicable, shall vest in four approximately equal installments on each of the first four anniversaries of March 14, 2022, in each case subject to the Reporting Person continuing in service through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock.
F2: The RSUs and options, as applicable, shall vest in four approximately equal installments on each of the first four anniversaries of March 14, 2022, in each case subject to the Reporting Person continuing in service through the applicable vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 04, 2022 Filed Apr 6, 2022 01:09 UTC | Bioventus Inc. BVS · Entity 4996 | SaleClass A Common Stock | 32,997 | $11.17 | $368,424.70 |
DisclosureSEC source: 0000899243-22-013953 · doc4.xml · nonDerivative · entry 2 Pavesio Alessandra · CIK 0001835185 · SVP & Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,309 F2 · kind: Reflects shares sold to cover taxes upon the vesting of RSUs on April 1, 2022 pursuant to a standing 10b5-1 instruction. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.12 to $11.28, inclusive. Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| April 01, 2022 Filed Apr 6, 2022 01:09 UTC | Bioventus Inc. BVS · Entity 4996 | Exercise / conversionRestricted Stock Units · Derivative | 61,476 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-013953 · doc4.xml · derivative · entry 3 Pavesio Alessandra · CIK 0001835185 · SVP & Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 61,476 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock. F4 · derivative.exercise_date: The RSUs vested on April 1, 2022. F4 · derivative.expiration_date: The RSUs vested on April 1, 2022. Read SEC document |
| April 01, 2022 Filed Apr 6, 2022 01:09 UTC | Bioventus Inc. BVS · Entity 4996 | Exercise / conversionClass A Common Stock | 61,476 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-013953 · doc4.xml · nonDerivative · entry 1 Pavesio Alessandra · CIK 0001835185 · SVP & Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 181,306 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock. Read SEC document |
| March 14, 2022 Filed Apr 21, 2023 21:05 UTC | Bioventus Inc. BVS · Entity 4996 | GrantStock Option (Right to Buy) · Derivative | 96,133 | $0.00 Strike: $1.16 | $0.00 |
DisclosureSEC source: 0001578563-23-000023 · primary_doc.xml · derivative · entry 2 Pavesio Alessandra · CIK 0001835185 · Fmr. SVP & Chief Science Off. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 96,133 Underlying: Class A Common Stock · 96,133 shares Expires 2032-03-13 F2 · derivative.exercise_date: The RSUs and options, as applicable, shall vest in four approximately equal installments on each of the first four anniversaries of March 14, 2022, in each case subject to the Reporting Person continuing in service through the applicable vesting date. Read SEC document |
| March 14, 2022 Filed Apr 21, 2023 21:05 UTC | Bioventus Inc. BVS · Entity 4996 | GrantRestricted Stock Units · Derivative | 35,545 | $0.00 | $0.00 |
DisclosureSEC source: 0001578563-23-000023 · primary_doc.xml · derivative · entry 1 Pavesio Alessandra · CIK 0001835185 · Fmr. SVP & Chief Science Off. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,545 Underlying: Class A Common Stock · 35,545 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock. F2 · derivative.exercise_date: The RSUs and options, as applicable, shall vest in four approximately equal installments on each of the first four anniversaries of March 14, 2022, in each case subject to the Reporting Person continuing in service through the applicable vesting date. F2 · derivative.expiration_date: The RSUs and options, as applicable, shall vest in four approximately equal installments on each of the first four anniversaries of March 14, 2022, in each case subject to the Reporting Person continuing in service through the applicable vesting date. Read SEC document |
| February 14, 2022 Filed Feb 16, 2022 23:29 UTC | Bioventus Inc. BVS · Entity 4996 | SaleClass A Common Stock | 433 | $11.99 | $5,191.67 |
DisclosureSEC source: 0000899243-22-006658 · doc4.xml · nonDerivative · entry 1 Pavesio Alessandra · CIK 0001835185 · SVP & Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,830 F1 · shares: Reflects shares sold to cover taxes upon the vesting of restricted stock units on February 11, 2022 pursuant to a standing 10b5-1 instruction. Read SEC document |
| February 11, 2022 Filed Feb 16, 2022 02:53 UTC | Bioventus Inc. BVS · Entity 4996 | Exercise / conversionRestricted Stock Units · Derivative | 1,470 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-006562 · doc4.xml · derivative · entry 2 Pavesio Alessandra · CIK 0001835185 · SVP & Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 1,470 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Class A common stock. F2 · derivative.exercise_date: The restricted stock units vested on February 11, 2022. F2 · derivative.expiration_date: The restricted stock units vested on February 11, 2022. Read SEC document |
| February 11, 2022 Filed Feb 16, 2022 02:53 UTC | Bioventus Inc. BVS · Entity 4996 | Exercise / conversionClass A Common Stock | 1,470 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-006562 · doc4.xml · nonDerivative · entry 1 Pavesio Alessandra · CIK 0001835185 · SVP & Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,263 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Class A common stock. Read SEC document |
| February 10, 2022 Filed Feb 15, 2022 01:43 UTC | Bioventus Inc. BVS · Entity 4996 | Exercise / conversionPhantom Profit Units · Derivative | 191,708 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-006333 · doc4.xml · derivative · entry 3 Pavesio Alessandra · CIK 0001835185 · SVP & CHIEF SCIENCE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 191,708 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Phantom Profit Unit represented a contingent right to receive one share of Class A common stock and vested on the one-year anniversary of the consummation of the Isuser's initial public offering. F1 · derivative.exercise_date: Each Phantom Profit Unit represented a contingent right to receive one share of Class A common stock and vested on the one-year anniversary of the consummation of the Isuser's initial public offering. F1 · derivative.expiration_date: Each Phantom Profit Unit represented a contingent right to receive one share of Class A common stock and vested on the one-year anniversary of the consummation of the Isuser's initial public offering. Read SEC document |
| February 10, 2022 Filed Feb 15, 2022 01:43 UTC | Bioventus Inc. BVS · Entity 4996 | Tax withholdingClass A Common Stock | 73,915 | $12.88 | $952,025.20 |
DisclosureSEC source: 0000899243-22-006333 · doc4.xml · nonDerivative · entry 2 Pavesio Alessandra · CIK 0001835185 · SVP & CHIEF SCIENCE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,793 Read SEC document |
| February 10, 2022 Filed Feb 15, 2022 01:43 UTC | Bioventus Inc. BVS · Entity 4996 | Exercise / conversionClass A Common Stock | 191,708 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-006333 · doc4.xml · nonDerivative · entry 1 Pavesio Alessandra · CIK 0001835185 · SVP & CHIEF SCIENCE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 192,708 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Phantom Profit Unit represented a contingent right to receive one share of Class A common stock and vested on the one-year anniversary of the consummation of the Isuser's initial public offering. Read SEC document |
| April 01, 2021 Filed Apr 5, 2021 20:38 UTC | Bioventus Inc. BVS · Entity 4996 | GrantStock Options · Derivative | 4,900 | $0.00 Strike: $15.23 | $0.00 |
DisclosureSEC source: 0000899243-21-014846 · doc4.xml · derivative · entry 3 Pavesio Alessandra · CIK 0001835185 · SVP & Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,900 Underlying: Class A Common Stock · 4,900 shares Expires 2031-03-31 F3 · derivative.exercise_date: The stock option vests in four equal annual installments beginning on April 1, 2022. Read SEC document |
| April 01, 2021 Filed Apr 5, 2021 20:38 UTC | Bioventus Inc. BVS · Entity 4996 | GrantRestricted Stock Units · Derivative | 61,476 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-014846 · doc4.xml · derivative · entry 2 Pavesio Alessandra · CIK 0001835185 · SVP & Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,476 Underlying: Class A Common Stock · 61,476 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Class A common stock. F2 · derivative.exercise_date: The restricted stock units vest on April 1, 2022 and have no expiration date. F2 · derivative.expiration_date: The restricted stock units vest on April 1, 2022 and have no expiration date. Read SEC document |
| February 11, 2021 Filed Feb 16, 2021 23:06 UTC | Bioventus Inc. BVS · Entity 4996 | GrantRestricted Stock Units · Derivative | 1,470 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-006739 · doc4.xml · derivative · entry 1 Pavesio Alessandra · CIK 0001835185 · SVP & Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,470 Underlying: Class A Common Stock · 1,470 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Class A common stock. F2 · derivative.exercise_date: The restricted stock units vest on February 11, 2022. F2 · derivative.expiration_date: The restricted stock units vest on February 11, 2022. Read SEC document |
| February 11, 2021 Filed Apr 5, 2021 20:38 UTC | Bioventus Inc. BVS · Entity 4996 | PurchaseCommon Stock | 1,000 | $13.00 | $13,000.00 |
DisclosureSEC source: 0000899243-21-014846 · doc4.xml · nonDerivative · entry 1 Pavesio Alessandra · CIK 0001835185 · SVP & Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.